{"id":"NCT01040052","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"A Study to Assess the Safety of Adacel® Vaccine","officialTitle":"A Bridging Study to Assess the Safety of the Vaccine Adacel® in a Clinical Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2010-02","completion":"2010-04","firstPosted":"2009-12-25","resultsPosted":"2011-03-29","lastUpdate":"2016-05-16"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)","otherNames":["Adacel®"]}],"arms":[{"label":"Study Group","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to describe the safety of Adacel® vaccination in adults subjects in Vietnam. This study is conducted in accordance with Vietnamese regulation in support to Adacel® registration.\n\nPrimary objective:\n\nTo monitor the adverse effects of the vaccine ADACEL® from day 0 to day 30 after immunization.","primaryOutcome":{"measure":"Number of Participants Reporting at Least One Solicited Local or Systemic Reaction Post-Vaccination With ADACEL® Vaccine","timeFrame":"Days 0-7 Post-vaccination","effectByArm":[{"arm":"ADACEL® Vaccine Group","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Injection site pain","Tiredeness","Headache"]}}